JP2010500376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500376A5 JP2010500376A5 JP2009523988A JP2009523988A JP2010500376A5 JP 2010500376 A5 JP2010500376 A5 JP 2010500376A5 JP 2009523988 A JP2009523988 A JP 2009523988A JP 2009523988 A JP2009523988 A JP 2009523988A JP 2010500376 A5 JP2010500376 A5 JP 2010500376A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- alkenyl
- aryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 57
- 125000003118 aryl group Chemical group 0.000 claims 37
- 229910052739 hydrogen Inorganic materials 0.000 claims 35
- 125000001072 heteroaryl group Chemical group 0.000 claims 33
- 125000000753 cycloalkyl group Chemical group 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 31
- -1 amino, substituted amino Chemical group 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 25
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 24
- 125000000547 substituted alkyl group Chemical group 0.000 claims 24
- 125000003342 alkenyl group Chemical group 0.000 claims 23
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000000304 alkynyl group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 125000004429 atom Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 3
- 208000027932 Collagen disease Diseases 0.000 claims 3
- 208000017701 Endocrine disease Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 208000025747 Rheumatic disease Diseases 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000004984 dialkylaminoalkoxy group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 208000014951 hematologic disease Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 230000001613 neoplastic effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000005001 aminoaryl group Chemical group 0.000 claims 2
- 125000005427 anthranyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 2
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000006550 alkoxycarbonyl aryl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 230000003262 anti-osteoporosis Effects 0.000 claims 1
- 230000002137 anti-vascular effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 1
- 125000005418 aryl aryl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000005026 carboxyaryl group Chemical group 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005027 hydroxyaryl group Chemical group 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004953 trihalomethyl group Chemical group 0.000 claims 1
- 0 C*c1nc(*)n[o]1 Chemical compound C*c1nc(*)n[o]1 0.000 description 3
- CZDXRHKFBHJWCS-YHYXMXQVSA-N C/C=C(/CC(C)=C1C=C)\C1=C Chemical compound C/C=C(/CC(C)=C1C=C)\C1=C CZDXRHKFBHJWCS-YHYXMXQVSA-N 0.000 description 1
- HDTBNIHMJISCOO-BYPYZUCNSA-N C[C@@H]1NSC(C)=C1 Chemical compound C[C@@H]1NSC(C)=C1 HDTBNIHMJISCOO-BYPYZUCNSA-N 0.000 description 1
- DQSHFKPKFISSNM-UHFFFAOYSA-N Cc1nc(cccc2)c2[o]1 Chemical compound Cc1nc(cccc2)c2[o]1 DQSHFKPKFISSNM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83649606P | 2006-08-09 | 2006-08-09 | |
| US11/835,438 US8034940B2 (en) | 2006-08-09 | 2007-08-08 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| PCT/US2007/075543 WO2008021926A2 (en) | 2006-08-09 | 2007-08-09 | Modulators of glucocorticoid receptor, and/or ap-1, and/or nf-kb activity and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010500376A JP2010500376A (ja) | 2010-01-07 |
| JP2010500376A5 true JP2010500376A5 (enExample) | 2010-09-02 |
Family
ID=39052386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523988A Withdrawn JP2010500376A (ja) | 2006-08-09 | 2007-08-09 | グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8034940B2 (enExample) |
| EP (1) | EP2049507A2 (enExample) |
| JP (1) | JP2010500376A (enExample) |
| KR (1) | KR20090038930A (enExample) |
| CN (1) | CN101528718B (enExample) |
| AR (1) | AR062312A1 (enExample) |
| AU (1) | AU2007286221A1 (enExample) |
| BR (1) | BRPI0716641A2 (enExample) |
| CA (1) | CA2660318A1 (enExample) |
| CL (1) | CL2007002330A1 (enExample) |
| EA (1) | EA200900291A1 (enExample) |
| IL (1) | IL196814A0 (enExample) |
| MX (1) | MX2009001220A (enExample) |
| NO (1) | NO20090564L (enExample) |
| PE (1) | PE20081314A1 (enExample) |
| TW (1) | TW200815454A (enExample) |
| WO (1) | WO2008021926A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010508358A (ja) | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用 |
| EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
| EP2078015B1 (en) | 2006-11-01 | 2012-03-21 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| WO2008057856A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| CN101990541A (zh) * | 2008-02-07 | 2011-03-23 | 百时美施贵宝公司 | 糖皮质激素受体、AP-1和/或NF-κB活性的稠合杂芳基调节剂及其用途 |
| CA2721060A1 (en) * | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| US8791258B2 (en) * | 2008-06-10 | 2014-07-29 | The Regents Of The University Of California | Pro-fluorescent probes |
| WO2009158380A1 (en) * | 2008-06-24 | 2009-12-30 | Bristol-Myers Squibb Company | Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof |
| US20110112299A1 (en) * | 2008-07-03 | 2011-05-12 | Kyowa Hakko Kirin Co., Ltd. | Tetracyclic compound |
| WO2011081173A1 (ja) * | 2009-12-29 | 2011-07-07 | 協和発酵キリン株式会社 | 四環系化合物 |
| US9845512B2 (en) * | 2010-01-15 | 2017-12-19 | Rigel Pharmaceuticals, Inc. | Screening assay employing Dex and GDF8 |
| US9796720B2 (en) | 2013-08-22 | 2017-10-24 | Bristol-Myers Squibb Company | Imidazole-derived modulators of the glucocorticoid receptor |
| WO2015027021A1 (en) | 2013-08-22 | 2015-02-26 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
| WO2016123244A1 (en) * | 2015-01-27 | 2016-08-04 | Indicator Systems International, Inc. | Fluorescein polymer conjugates |
| WO2018030550A1 (en) | 2016-08-09 | 2018-02-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds with an ror(gamma)t modulating activity |
| WO2019079614A1 (en) * | 2017-10-19 | 2019-04-25 | Tempest Therapeutics, Inc. | PICOLINAMIDE COMPOUNDS |
| CN113862704B (zh) * | 2021-11-15 | 2023-07-21 | 南昌航空大学 | 一种9-芳基呫吨类化合物的制备方法 |
| AR127618A1 (es) | 2021-11-29 | 2024-02-14 | Bayer Ag | Dihidropiranopiridinas sustituidas, sales o n-óxidos de las mismas y su uso como sustancias herbicidamente activas |
| CN117105821A (zh) * | 2023-04-18 | 2023-11-24 | 重庆普佑制药有限公司 | 一种沙库比曲中间体的制备方法 |
| CN117105820A (zh) * | 2023-07-12 | 2023-11-24 | 上海阿拉丁生化科技股份有限公司 | 一种4-氟苯乙基异氰酸酯的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US5053414A (en) | 1988-04-08 | 1991-10-01 | Ono Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| US5073566A (en) | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
| EP0636619A1 (en) | 1991-09-13 | 1995-02-01 | Sankyo Company Limited | Tricyclic heterocyclic compound |
| US5453421A (en) | 1992-09-11 | 1995-09-26 | E. R. Squibb & Sons, Inc. | Aryl and heterocyclic substituted propenamide derivatives |
| TW306916B (enExample) | 1994-09-13 | 1997-06-01 | Ciba Geigy Ag | |
| DE19610882A1 (de) | 1996-03-20 | 1997-09-25 | Dresden Arzneimittel | Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PL332593A1 (en) | 1996-10-04 | 1999-09-27 | Novo Nordisk As | N-substituted azaheterocyclic compounds |
| EP0927166A1 (en) | 1997-02-14 | 1999-07-07 | Bayer Corporation | Amides as npy5 receptor antagonists |
| CO4980885A1 (es) | 1997-12-29 | 2000-11-27 | Ortho Mcneil Pharm Inc | Compuestos de trifenilpropanamida utiles en el tratamiento de inflamaciones y metodos para preparar dicho compuesto |
| EP1183229B1 (en) | 1999-05-17 | 2005-10-26 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| CA2468544A1 (en) | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| WO2005066153A1 (en) | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| JP4846596B2 (ja) | 2003-12-19 | 2011-12-28 | イーライ リリー アンド カンパニー | 三環系のステロイドホルモン核内受容体モジュレータ |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| EP1828144A2 (en) | 2004-11-12 | 2007-09-05 | OSI Pharmaceuticals, Inc. | Integrin antagonists useful as anticancer agents |
| US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| JP4943826B2 (ja) | 2005-11-25 | 2012-05-30 | 田辺三菱製薬株式会社 | 医薬組成物 |
| EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
| WO2008057856A2 (en) | 2006-11-01 | 2008-05-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
| JP2010508358A (ja) | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、ＡＰ−１、および／またはＮＦ−κＢ活性の調節剤、並びにその使用 |
| EP2078015B1 (en) | 2006-11-01 | 2012-03-21 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof |
-
2007
- 2007-08-08 US US11/835,438 patent/US8034940B2/en active Active
- 2007-08-09 MX MX2009001220A patent/MX2009001220A/es not_active Application Discontinuation
- 2007-08-09 AU AU2007286221A patent/AU2007286221A1/en not_active Abandoned
- 2007-08-09 EP EP07800057A patent/EP2049507A2/en not_active Withdrawn
- 2007-08-09 AR ARP070103536A patent/AR062312A1/es not_active Application Discontinuation
- 2007-08-09 CN CN200780037118XA patent/CN101528718B/zh not_active Expired - Fee Related
- 2007-08-09 TW TW096129426A patent/TW200815454A/zh unknown
- 2007-08-09 BR BRPI0716641-9A patent/BRPI0716641A2/pt not_active Application Discontinuation
- 2007-08-09 PE PE2007001067A patent/PE20081314A1/es not_active Application Discontinuation
- 2007-08-09 WO PCT/US2007/075543 patent/WO2008021926A2/en not_active Ceased
- 2007-08-09 CL CL200702330A patent/CL2007002330A1/es unknown
- 2007-08-09 CA CA002660318A patent/CA2660318A1/en not_active Abandoned
- 2007-08-09 JP JP2009523988A patent/JP2010500376A/ja not_active Withdrawn
- 2007-08-09 EA EA200900291A patent/EA200900291A1/ru unknown
- 2007-08-09 KR KR1020097004788A patent/KR20090038930A/ko not_active Withdrawn
-
2009
- 2009-02-01 IL IL196814A patent/IL196814A0/en unknown
- 2009-02-05 NO NO20090564A patent/NO20090564L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11724982B2 (en) | 2014-10-10 | 2023-08-15 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500376A5 (enExample) | ||
| JP2015536986A5 (enExample) | ||
| ES2521672T3 (es) | Formulaciones farmacéuticas para el tratamiento del cáncer | |
| JP2018070614A5 (enExample) | ||
| JP2007505933A5 (enExample) | ||
| RU2015121424A (ru) | Комбинированная терапия | |
| JP2009541223A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| JP2005533748A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2014512356A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2014528464A5 (enExample) | ||
| JP2018501315A5 (enExample) | ||
| RU2015117647A (ru) | Новые производные пиразола | |
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| JP2019502686A5 (enExample) | ||
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| JP2011518168A5 (enExample) | ||
| JPWO2020163823A5 (enExample) | ||
| RU2007116987A (ru) | Новые соединения | |
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака | |
| JP2005508969A5 (enExample) | ||
| JP2012509313A5 (enExample) |